Karyopharm Therapeutics Inc. (KPTI) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
36/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinKPTI / S&P 75.40% / 15.20% |
LoseKPTI / S&P 6.81% / 15.00% |
LoseKPTI / S&P -1.10% / 50.40% |
| 2026-Q10/3 |
LoseKPTI / S&P -24.32% / -4.33% |
LoseKPTI / S&P 6.33% / 11.30% |
LoseKPTI / S&P 24.18% / 27.70% |
| 2025-Q42/3 |
WinKPTI / S&P 12.54% / 2.65% |
LoseKPTI / S&P 0.57% / 9.00% |
WinKPTI / S&P 17.29% / 13.40% |
| 2025-Q31/3 |
WinKPTI / S&P 51.74% / 8.12% |
LoseKPTI / S&P -3.98% / 4.61% |
LoseKPTI / S&P -50.93% / 13.45% |
| 2025-Q21/3 |
WinKPTI / S&P 15.24% / 10.94% |
LoseKPTI / S&P -5.77% / 4.83% |
LoseKPTI / S&P -44.12% / 10.63% |
| 2025-Q10/3 |
LoseKPTI / S&P -63.12% / -4.27% |
LoseKPTI / S&P 1.19% / 4.98% |
LoseKPTI / S&P -43.49% / 10.57% |
| 2024-Q40/3 |
LoseKPTI / S&P -18.55% / 2.41% |
LoseKPTI / S&P -0.55% / 5.25% |
LoseKPTI / S&P -18.73% / 6.15% |
| 2024-Q31/3 |
LoseKPTI / S&P -4.38% / 5.89% |
LoseKPTI / S&P 1.77% / 5.89% |
WinKPTI / S&P 2157.25% / 6.11% |
| 2024-Q21/3 |
LoseKPTI / S&P -42.52% / 4.28% |
LoseKPTI / S&P -0.23% / 5.38% |
WinKPTI / S&P 1682.19% / 5.12% |
| 2024-Q12/3 |
WinKPTI / S&P 74.57% / 10.56% |
LoseKPTI / S&P -5.16% / 5.71% |
WinKPTI / S&P 1203.91% / 5.59% |
| 2023-Q41/3 |
LoseKPTI / S&P -35.45% / 11.69% |
LoseKPTI / S&P -7.03% / 6.81% |
WinKPTI / S&P 830.20% / 7.78% |
| 2023-Q31/3 |
LoseKPTI / S&P -25.14% / -3.27% |
LoseKPTI / S&P -41.60% / 7.52% |
WinKPTI / S&P 21.30% / -5.03% |
| 2023-Q21/3 |
LoseKPTI / S&P -53.98% / 8.74% |
LoseKPTI / S&P -41.90% / 9.50% |
WinKPTI / S&P 10.61% / -8.57% |
| 2023-Q12/3 |
WinKPTI / S&P 14.41% / 7.50% |
LoseKPTI / S&P -36.77% / 10.77% |
WinKPTI / S&P 26.95% / -15.69% |
| 2022-Q40/3 |
LoseKPTI / S&P -37.73% / 7.56% |
LoseKPTI / S&P -25.14% / 11.88% |
LoseKPTI / S&P KPTI unavailable / -17.99% |
| 2022-Q32/3 |
WinKPTI / S&P 21.06% / -4.88% |
WinKPTI / S&P 110.50% / 13.47% |
LoseKPTI / S&P KPTI unavailable / -1.41% |
| 2022-Q21/3 |
LoseKPTI / S&P -38.81% / -16.10% |
WinKPTI / S&P 145.67% / 13.71% |
LoseKPTI / S&P KPTI unavailable / 11.04% |
| 2022-Q12/3 |
WinKPTI / S&P 14.62% / -4.60% |
WinKPTI / S&P 106.90% / 15.97% |
LoseKPTI / S&P KPTI unavailable / 42.23% |
| 2021-Q41/3 |
LoseKPTI / S&P 10.48% / 11.03% |
WinKPTI / S&P 94.12% / 15.00% |
LoseKPTI / S&P KPTI unavailable / 96.40% |
| 2021-Q31/3 |
LoseKPTI / S&P -43.60% / 0.58% |
WinKPTI / S&P 30.27% / 10.77% |
LoseKPTI / S&P KPTI unavailable / 69.42% |
| 2021-Q21/3 |
LoseKPTI / S&P -1.90% / 8.55% |
WinKPTI / S&P 23.40% / 6.58% |
LoseKPTI / S&P KPTI unavailable / 51.81% |
| 2021-Q11/3 |
LoseKPTI / S&P -32.04% / 6.17% |
WinKPTI / S&P 92.28% / -1.06% |
LoseKPTI / S&P KPTI unavailable / 7.39% |
| 2020-Q41/3 |
LoseKPTI / S&P 6.03% / 12.15% |
WinKPTI / S&P 164.31% / -3.72% |
LoseKPTI / S&P KPTI unavailable / -33.42% |
| 2020-Q31/3 |
LoseKPTI / S&P -22.91% / 8.93% |
WinKPTI / S&P 295.95% / -2.04% |
LoseKPTI / S&P KPTI unavailable / -27.10% |
| 2020-Q21/3 |
LoseKPTI / S&P -1.41% / 20.54% |
WinKPTI / S&P 721.33% / -0.46% |
LoseKPTI / S&P KPTI unavailable / -27.11% |
| 2020-Q12/3 |
WinKPTI / S&P 0.21% / -19.60% |
WinKPTI / S&P 187.33% / 3.47% |
LoseKPTI / S&P KPTI unavailable / -14.75% |
| 2019-Q42/3 |
WinKPTI / S&P 99.27% / 9.07% |
WinKPTI / S&P 34.80% / 5.36% |
LoseKPTI / S&P KPTI unavailable / 2.99% |
| 2019-Q31/3 |
WinKPTI / S&P 60.60% / 1.70% |
LoseKPTI / S&P -27.35% / 5.02% |
LoseKPTI / S&P KPTI unavailable / 0.21% |
| 2019-Q20/3 |
LoseKPTI / S&P 2.57% / 4.30% |
LoseKPTI / S&P KPTI unavailable / 6.64% |
LoseKPTI / S&P KPTI unavailable / 8.65% |
| 2019-Q10/3 |
LoseKPTI / S&P -37.67% / 13.65% |
LoseKPTI / S&P KPTI unavailable / 8.12% |
LoseKPTI / S&P KPTI unavailable / 14.29% |
| 2018-Q40/3 |
LoseKPTI / S&P -44.98% / -13.52% |
LoseKPTI / S&P KPTI unavailable / 9.05% |
LoseKPTI / S&P KPTI unavailable / 18.23% |
| 2018-Q30/3 |
LoseKPTI / S&P 0.24% / 7.71% |
LoseKPTI / S&P KPTI unavailable / 10.21% |
LoseKPTI / S&P KPTI unavailable / 19.06% |
| 2018-Q21/3 |
WinKPTI / S&P 26.60% / 3.43% |
LoseKPTI / S&P KPTI unavailable / 9.03% |
LoseKPTI / S&P KPTI unavailable / 14.46% |
| 2018-Q11/3 |
WinKPTI / S&P 39.79% / -0.76% |
LoseKPTI / S&P KPTI unavailable / 7.68% |
LoseKPTI / S&P KPTI unavailable / 12.46% |
| 2017-Q40/3 |
LoseKPTI / S&P -12.57% / 6.64% |
LoseKPTI / S&P KPTI unavailable / 7.03% |
LoseKPTI / S&P KPTI unavailable / 13.82% |
| 2017-Q31/3 |
WinKPTI / S&P 21.33% / 4.48% |
LoseKPTI / S&P KPTI unavailable / 5.68% |
LoseKPTI / S&P KPTI unavailable / 17.57% |
| 2017-Q20/3 |
LoseKPTI / S&P -29.52% / 3.09% |
LoseKPTI / S&P KPTI unavailable / 4.83% |
LoseKPTI / S&P KPTI unavailable / 17.74% |
| 2017-Q11/3 |
WinKPTI / S&P 36.60% / 6.07% |
LoseKPTI / S&P KPTI unavailable / 3.67% |
LoseKPTI / S&P KPTI unavailable / 13.32% |
| 2016-Q40/3 |
LoseKPTI / S&P -3.39% / 3.82% |
LoseKPTI / S&P KPTI unavailable / 2.09% |
LoseKPTI / S&P KPTI unavailable / 7.05% |
| 2016-Q31/3 |
WinKPTI / S&P 45.01% / 3.85% |
LoseKPTI / S&P KPTI unavailable / 0.20% |
LoseKPTI / S&P KPTI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | KPTI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -72.71% | 20.78% |
| Annualized return | -72.71% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | KPTI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.79% | 83.14% |
| Annualized return | -53.34% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | KPTI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.83% | 319.30% |
| Annualized return | -35.93% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |